8,700 Studies Reviewed. 87.0% Found Biological Effects. The Evidence is Clear.
Shield Your Body
Cancer & Tumors

Akbarnejad, M. Esmaeeli, Y, Masoumi-Ardakani, L. Mohammadipoor-Ghasemabad, and H

Bioeffects Seen

Ahmadi-Zeidabadi, M., Z. · 2019

Share:

Controlled electromagnetic fields successfully treat deadly brain cancer, proving EMF effects depend entirely on frequency, intensity, and application.

Plain English Summary

Summary written for general audiences

This 2019 review examines tumor-treating fields (TTFields), a cancer therapy that uses low-intensity, intermediate-frequency electric fields to treat deadly brain tumors called glioblastomas. The research shows TTFields significantly extends patient survival by disrupting cancer cell division and DNA repair. Clinical trials demonstrate this electromagnetic therapy works as the fourth most effective treatment option for these aggressive brain cancers.

Why This Matters

This study represents a fascinating paradox in EMF research. While we rightfully concern ourselves with potential health risks from everyday EMF exposure, here we see controlled electromagnetic fields being harnessed as a life-saving medical treatment. TTFields therapy delivers precisely calibrated electric fields that selectively target cancer cells while sparing healthy tissue. The science demonstrates that electromagnetic fields, when applied with surgical precision, can disrupt the very cellular processes that make glioblastoma so deadly. What this means for you is understanding that frequency, intensity, and application method matter enormously in EMF effects. The same physical phenomenon that raises health concerns in uncontrolled exposures becomes a powerful therapeutic tool when properly directed.

Exposure Information

Specific exposure levels were not quantified in this study.

Cite This Study
Ahmadi-Zeidabadi, M., Z. (2019). Akbarnejad, M. Esmaeeli, Y, Masoumi-Ardakani, L. Mohammadipoor-Ghasemabad, and H.
Show BibTeX
@article{akbarnejad_m_esmaeeli_y_masoumi_ardakani_l_mohammadipoor_ghasemabad_and_h_ce3948,
  author = {Ahmadi-Zeidabadi and M. and Z.},
  title = {Akbarnejad, M. Esmaeeli, Y, Masoumi-Ardakani, L. Mohammadipoor-Ghasemabad, and H},
  year = {2019},
  doi = {10.3390/cancers14153669},
  
}
DOI: 10.3390/cancers14153669PubMed: 35954334

Quick Questions About This Study

TTFields are low-intensity, intermediate-frequency electric fields delivered to brain tumor sites. This FDA-approved therapy disrupts cancer cell division and DNA repair, significantly extending survival for glioblastoma patients when combined with standard treatments.
TTFields work through multiple mechanisms including disrupting cell division, delaying DNA repair, enhancing autophagy, inhibiting metabolism and blood vessel formation, and limiting cancer cell migration. They also strengthen immune responses against tumors.
Clinical trials show TTFields therapy has acceptable adverse events and is well-tolerated. The targeted electromagnetic fields selectively affect rapidly dividing cancer cells while causing minimal damage to healthy brain tissue.
Randomized clinical trials demonstrate TTFields substantially prolongs patient survival compared to standard care alone. It ranks as the fourth most effective treatment because it provides meaningful survival benefits for this otherwise fatal cancer.
Despite proven effectiveness, overall acceptance of TTFields in real-world clinical practice remains low. This may be due to the relatively recent approval, cost considerations, or unfamiliarity with electromagnetic therapy approaches.